These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 712208)

  • 1. Effects of glucocorticoids on osteoclast-activating factor.
    Strumpf M; Kowalski MA; Mundy GR
    J Lab Clin Med; 1978 Nov; 92(5):772-8. PubMed ID: 712208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Big and little forms of osteoclast activating factor.
    Mundy GR; Raisz LG; Shapiro JL; Bandelin JG; Turcotte RJ
    J Clin Invest; 1977 Jul; 60(1):122-8. PubMed ID: 874077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial purification of osteoclast-activating factor from phytohemagglutinin-stimulated human leukocytes.
    Luben RA; Mundy GR; Trummel CL; Raisz LG
    J Clin Invest; 1974 May; 53(5):1473-80. PubMed ID: 4825237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.
    Torcia M; Lucibello M; Vannier E; Fabiani S; Miliani A; Guidi G; Spada O; Dower SK; Sims JE; Shaw AR; Dinarello CA; Garaci E; Cozzolino F
    Exp Hematol; 1996 Jul; 24(8):868-74. PubMed ID: 8690044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observations on the mechanism of bone resorption induced by multiple myeloma marrow culture fluids and partially purified osteoclast-activating factor.
    Josse RG; Murray TM; Mundy GR; Jez D; Heersche JN
    J Clin Invest; 1981 May; 67(5):1472-81. PubMed ID: 6262378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of osteoclast activating factor from human leukocytes on bone metabolism.
    Raisz LG; Luben RA; Mundy GR; Dietrich JW; Horton JE; Trummel CL
    J Clin Invest; 1975 Aug; 56(2):408-13. PubMed ID: 1171115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia. Role of an osteoclast activating factor-like substance and a mechanism of action for glucocorticoid therapy.
    Mundy GR; Rick ME; Turcotte R; Kowalski MA
    Am J Med; 1978 Oct; 65(4):600-6. PubMed ID: 707520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effects of osteoclast-activating factor (OAF) on the absorption of alveolar bone. 1. Production and purification of OAF (author's transl)].
    Marumoto Y; Kusunoki K; Fijihashi H; Osaka H; Nakamura Y; Ikeda K
    Nihon Shishubyo Gakkai Kaishi; 1982 Mar; 24(1):121-7. PubMed ID: 6980245
    [No Abstract]   [Full Text] [Related]  

  • 9. Release of osteoclast activating factor by normal human peripheral blood leukocytes.
    Trummel CL; Mundy GR; Raisz LG
    J Lab Clin Med; 1975 Jun; 85(6):1001-7. PubMed ID: 1138018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostaglandins are necessary for osteoclast-activating factor production by activated peripheral blood leukocytes.
    Yoneda T; Mundy GR
    J Exp Med; 1979 Jan; 149(1):279-83. PubMed ID: 105076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of osteoclast-activating factor by normal human peripheral blood rosetting and nonrosetting lymphocytes.
    Chen P; Trummel C; Horton J; Baker JJ; Oppenheim JJ
    Eur J Immunol; 1976 Oct; 6(10):732-6. PubMed ID: 797286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo.
    Uy HL; Mundy GR; Boyce BF; Story BM; Dunstan CR; Yin JJ; Roodman GD; Guise TA
    Cancer Res; 1997 Aug; 57(15):3194-9. PubMed ID: 9242449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoids impair bone resorptive activity and viability of osteoclasts disaggregated from neonatal rat long bones.
    Tobias J; Chambers TJ
    Endocrinology; 1989 Sep; 125(3):1290-5. PubMed ID: 2759026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma.
    Durie BG; Salmon SE; Mundy GR
    Br J Haematol; 1981 Jan; 47(1):21-30. PubMed ID: 7437344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity.
    Pederson L; Winding B; Foged NT; Spelsberg TC; Oursler MJ
    Cancer Res; 1999 Nov; 59(22):5849-55. PubMed ID: 10582709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
    Oyajobi BO; Anderson DM; Traianedes K; Williams PJ; Yoneda T; Mundy GR
    Cancer Res; 2001 Mar; 61(6):2572-8. PubMed ID: 11289133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro.
    Gowen M; Mundy GR
    J Immunol; 1986 Apr; 136(7):2478-82. PubMed ID: 3081643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hypercalcemia in multiple myeloma].
    Takahashi T
    Nihon Rinsho; 1995 Mar; 53(3):710-4. PubMed ID: 7699910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunologic mechanisms of regulating calcium metabolism in human bone tissue (production of osteoclast-activating factor) during long-term anti-orthostatic hypokinesia].
    Konstantinova IV; Lesniak AT; Bozhikov NV; Uchakin PN
    Kosm Biol Aviakosm Med; 1989; 23(3):38-42. PubMed ID: 2788231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithetic effects of ryanodine and ruthenium red on osteoclast-mediated bone resorption and intracellular calcium concentrations.
    Ritchie CK; Strei TA; Maercklein PB; Fitzpatrick LA
    J Cell Biochem; 1995 Oct; 59(2):281-9. PubMed ID: 8904321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.